Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy-Reference-Cited by-同舟云学术

Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy

Published:2019-06-27 Issue:16 Volume:62 Page:7400-7416
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Miller Michael M.¹,Banville Jacques²,Friends Todd J.¹,Gagnon Mark²,Hangeland Jon J.¹^ORCID,Lavallée Jean-François²,Martel Alain²,O’Grady Harold¹,Rémillard Roger²,Ruediger Edward²,Tremblay François²,Posy Shana L.³,Allegretto Nick J.¹,Guarino Victor R.¹,Harden David G.⁴,Harper Timothy W.¹,Hartl Karen¹,Josephs Jonathan¹,Malmstrom Sarah¹,Watson Carol¹,Yang Yanou¹,Zhang Ge¹,Wong Pancras¹,Yang Jing¹,Bouvier Michel²⁵^ORCID,Seiffert Dietmar A.¹,Wexler Ruth R.¹,Lawrence R. Michael¹,Priestley E. Scott¹^ORCID,Marinier Anne²

Affiliation:

1. Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States

2. Institute for Research in Immunology and Cancer, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada

3. Bristol-Myers Squibb Research & Development, 3551 Lawrenceville Road, Princeton, New Jersey 08540, United States

4. Bristol-Myers Squibb Research & Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States

5. Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Québec H3C 3J7, Canada

Funder

Bristol-Myers Squibb

Minist?re de l'?conomie, de la Science et de l'Innovation - Qu?bec

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00186

Reference40 articles.

1. Heart Disease and Stroke Statistics—2016 Update

2. Antiplatelet Drugs

3. Dual Antiplatelet Therapy with Prasugrel or Ticagrelor Versus Clopidogrel in Interventional Cardiology

4. Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization

5. Measured Drug Effect and Cardiovascular Outcomes in Patients Receiving Platelet P2Y12Receptor Antagonists

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis;Journal of Medicinal Chemistry;2024-02-22

2. Therapeutic charisma of imidazo [2,1-b] [1,3,4]-thiadiazole analogues: a patent review;Pharmaceutical Patent Analyst;2023-07

3. Discovery of 7, 4′-dimethoxy-3-hydroxyflavone as a protease-activated receptor 4 antagonist with antithrombotic activity and less bleeding tendency in mice;Biochemical Pharmacology;2022-08

4. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4;Journal of Medicinal Chemistry;2022-06-22

5. Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013–2021);Expert Opinion on Therapeutic Patents;2022-02-01